• LAST PRICE
    1.1400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.0800/ 1
  • Ask / Lots
    1.5500/ 3
  • Open / Previous Close
    0.0000 / 1.1400
  • Day Range
    ---
  • 52 Week Range
    Low 1.0100
    High 12.2300
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.13
TimeVolumeGLS
09:32 ET2481.1
09:34 ET6071.1804
09:36 ET2001.12
09:38 ET1001.12
09:39 ET1001.12
09:41 ET3001.12
09:43 ET2001.12
09:56 ET1001.16
10:06 ET1001.16
10:12 ET2001.12
10:46 ET2151.14
10:48 ET1001.15
11:02 ET10001.2
11:08 ET1001.18
11:22 ET39331.15
11:26 ET2001.13
11:27 ET4001.13
11:29 ET2001.13
11:31 ET2001.13
11:33 ET5001.13
11:36 ET11001.13
11:40 ET1001.125
11:42 ET1001.125
11:44 ET1001.125
11:47 ET1001.125
11:58 ET1001.14
12:07 ET2001.13
12:16 ET1001.14
12:25 ET1001.13
12:30 ET1001.12
12:41 ET1001.13
01:03 ET2001.14
01:06 ET2001.135
01:50 ET1551.135
02:06 ET1001.13
02:08 ET5131.13
02:18 ET1001.11
03:50 ET7201.13
03:56 ET1001.15
03:57 ET7001.15
03:59 ET3001.14
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGLS
Gelesis Holdings Inc
81.7M
0.0x
---
United StatesSCYX
SCYNEXIS Inc
76.4M
-1.6x
---
United StatesEYEN
Eyenovia Inc
65.3M
-3.8x
---
United StatesHOOK
HOOKIPA Pharma Inc
79.3M
-0.7x
---
United StatesUG
United-Guardian Inc
56.6M
13.8x
+12.54%
United StatesVRCA
Verrica Pharmaceuticals Inc
120.4M
-2.0x
---
As of 2022-10-05

Company Information

Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.

Contact Information

Headquarters
501 Boylston Street, Suite 6102BOSTON, MA, United States 02116
Phone
857-327-7737
Fax
302-636-5454

Executives

President, Chief Executive Officer, Director, Co-Inventor
Yishai Zohar
Chief Financial Officer, Treasurer
Elliot Maltz
Chief Operating Officer, Chief Commercial Officer
David Pass
Chief Scientific Officer
Elaine Chiquette
Chief Medical Officer
Harry Leider

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$81.7M
Revenue (TTM)
---
Shares Outstanding
72.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
---
Book Value
$-0.25
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.